Business Context and Reporting Period
This Form 8-K was filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on January 4, 2016. The report covers the event of the company's common stock commencing regular way trading on the NYSE MKT under the symbol OCX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the commencement of regular way trading for OncoCyte Corporation's common stock on the NYSE MKT effective January 4, 2016.
Guidance, Outlook, and Risks
The filing includes a standard forward-looking statements disclaimer. It notes that actual results may differ materially from anticipated results due to factors detailed in the company's Form 10 under "Risk Factors." The company disclaims any obligation to update these statements except as required by law. No specific guidance or management commentary regarding future operations is provided in this document.
Investor Verification Checklist
- Verify the ticker symbol OCX on the NYSE MKT.
- Review the attached Press Release (Exhibit 99.1) for additional context on the listing.
- Consult the company's Form 10 for detailed risk factors and historical financial data.
- Confirm the company name is OncoCyte Corporation, as the input metadata referenced a different entity.